Chrysalis BioTherapeutics
Clinical-stage biopharmaceutical company developing a synthetic 23–amino-acid regenerative peptide (TP508) for systemic use to mitigate vascular damage, inflammation and tissue injury in acute respiratory distress syndrome (ARDS), radiation exposure, and as an adjunct to radiation therapy. The company conducts preclinical efficacy studies, GLP nonclinical safety testing, CMC/formulation development, IND-enabling activities and regulatory filings, and manages government-funded development programs.
Industries
Nr. of Employees
small (1-50)
Chrysalis BioTherapeutics
Products
Investigational thrombin‑derived regenerative peptide (TP508)
23–amino‑acid synthetic peptide under development for systemic administration to mitigate vascular damage, reduce inflammation and activate progenitor/stem cells for tissue repair in ARDS, radiation exposure, and to reduce normal tissue injury from radiation therapy.
TP508
A novel peptide drug product that reduces radiation therapy-induced neural inflammation and restores neural stem cells in the hippocampus of the brain, potentially mitigating radiation-induced brain damage and preventing cognitive impairment.
TP508 (Chrysalin®, rusalatide acetate)
TP508 is an injectable synthetic peptide drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS induced by viral infection (COVID19) or nuclear radiation. It activates stem cells to regenerate tissues and restore function, showing potential efficacy where previous drugs have failed. It is GMP manufactured and has demonstrated safety and efficacy in clinical trials for diabetic foot ulcers and fracture repair.
Chrysalin®
Chrysalin is a regenerative peptide drug initially developed for its wound healing properties, shown to significantly increase the complete healing of chronic ulcers in diabetic foot ulcer human clinical trials. It is being evaluated for the treatment of Cutaneous Radiation Injury (CRI) and Acute Respiratory Distress Syndrome (ARDS).
Investigational thrombin‑derived regenerative peptide (TP508)
23–amino‑acid synthetic peptide under development for systemic administration to mitigate vascular damage, reduce inflammation and activate progenitor/stem cells for tissue repair in ARDS, radiation exposure, and to reduce normal tissue injury from radiation therapy.
TP508
A novel peptide drug product that reduces radiation therapy-induced neural inflammation and restores neural stem cells in the hippocampus of the brain, potentially mitigating radiation-induced brain damage and preventing cognitive impairment.
TP508 (Chrysalin®, rusalatide acetate)
TP508 is an injectable synthetic peptide drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS induced by viral infection (COVID19) or nuclear radiation. It activates stem cells to regenerate tissues and restore function, showing potential efficacy where previous drugs have failed. It is GMP manufactured and has demonstrated safety and efficacy in clinical trials for diabetic foot ulcers and fracture repair.
Chrysalin®
Chrysalin is a regenerative peptide drug initially developed for its wound healing properties, shown to significantly increase the complete healing of chronic ulcers in diabetic foot ulcer human clinical trials. It is being evaluated for the treatment of Cutaneous Radiation Injury (CRI) and Acute Respiratory Distress Syndrome (ARDS).
Expertise Areas
- Preclinical radiation medical countermeasure development
- Regenerative peptide therapeutics
- ARDS and acute lung injury therapeutics
- Vascular and endothelial biology
Key Technologies
- Synthetic therapeutic peptides
- GMP peptide manufacturing
- Lyophilized vial formulation
- PEGylation for pharmacokinetic modification
News & Updates
Press release reporting preclinical studies where the investigational peptide reversed radiation-induced GI damage and increased survival in animal models; research supported by NIAID (Award Number R44AI086135).
Awarded a BARDA contract to support preclinical development of an investigational peptide as a nuclear medical countermeasure, including preclinical efficacy studies and options for additional funding to support pivotal studies and clinical trials.
BARDA executed options adding funding to continue development toward Emergency Use Authorization and Animal Rule approval, including safety studies, human safety/PK studies, assay development and large‑scale manufacturing.
Initiated a multi‑year contract with NIH/NIAID to develop the peptide as a countermeasure to increase survival and reduce delayed effects after nuclear exposure.
FDA Office of Orphan Product Development and EMA granted orphan designation to the lead investigational compound for treatment of acute radiation syndrome.
Company announced FDA permission to initiate human clinical testing (Phase I safety/PK) for systemic administration of the investigational peptide.
Press release reporting preclinical studies where the investigational peptide reversed radiation-induced GI damage and increased survival in animal models; research supported by NIAID (Award Number R44AI086135).
Awarded a BARDA contract to support preclinical development of an investigational peptide as a nuclear medical countermeasure, including preclinical efficacy studies and options for additional funding to support pivotal studies and clinical trials.
BARDA executed options adding funding to continue development toward Emergency Use Authorization and Animal Rule approval, including safety studies, human safety/PK studies, assay development and large‑scale manufacturing.
Initiated a multi‑year contract with NIH/NIAID to develop the peptide as a countermeasure to increase survival and reduce delayed effects after nuclear exposure.
FDA Office of Orphan Product Development and EMA granted orphan designation to the lead investigational compound for treatment of acute radiation syndrome.
Company announced FDA permission to initiate human clinical testing (Phase I safety/PK) for systemic administration of the investigational peptide.